Projet THERADNET (Horizon 2020, appel à projets 2019)
Action : Doctoral Networks
Panel : Life Sciences
Statut du projet : SIGNED

Radiotherapy alone or in multimodality approaches is applied in 45-60% of all cancer patients, but despite technical innovations approximately only 50% are cured. Disease recurrence may be due to regrowth of the primary tumor or metastatic outgrowth. Intrinsic and acquired resistance of the tumor and adverse reactions in the co-irradiated surrounding normal tissues dampen a successful therapy outcome. Substantial improvements are now expected from biologically optimized, personalized radiotherapy. This network is built on the premises that integration of novel-emerging radiobiological and tumor-biological concepts into current standard-of-care will improve outcome of radiotherapy-treated cancer patients. As the field of radiobiology is small in individual countries, it is essential to cooperate on the European level to achieve a critical mass for innovation in research and training. The partners in this network will stimulate outstanding science to understand the plasticity of an altered tumor metabolism and tumor microenvironment, including the immune system, prior to, and in response to radiotherapy, as well as related dose-limiting adverse effects in normal tissues. Research and development of novel combined treatment modalities in these areas will be performed in models as close as possible to the clinical situation to evaluate their potential to widen the therapeutic window beyond standard-of-care. Students will benefit from outstanding expertise and collaborations within academia and industry integrating novel concepts into translational cancer and radiation research. This will guarantee high employability in various sectors of cancer research and precision medicine. The European community will benefit from the pursuit of innovative hypotheses, training of new researchers, and dissemination of knowledge. By combatting a major death-related disease in Europe, this project will raise health and bring long-term benefit to the European and international community.

Mots clés : radiobiology, combined treatment modality, tumor metabolism, radioimmunobiology, dna damage, therapeutic window, resistance mechanism tumor cell plasticity

Participants :
- TU Dresden (Allemagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 505576.8 €
- Essen University Hospital (Allemagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 505576.8 €
- Maastricht University (Pays-Bas) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 531239.76 €
- University of Oxford (Royaume-Uni) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 606345.12 €
- Institut Curie (France) — Partner, beneficiary, Recherche, subvention : 549604.08 €
- Westdeutsches protonentherapiezentrum essen (wpe) ggmbh (Allemagne) — Partner, beneficiary, Autres, subvention : 252788.4 €
- University of Zurich (Suisse) — Coordinator, beneficiary, Enseignement supérieur ou secondaire, subvention : 562553.28 €
- Université Catholique de Louvain (Belgique) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 512640.0 €